Literature DB >> 3907341

Contribution of beta-lactamases to bacterial resistance and mechanisms to inhibit beta-lactamases.

H C Neu.   

Abstract

Resistance of bacteria to beta-lactam antibiotics has become a serious problem in the past several decades. Virtually all Staphylococcus aureus, and many Hemophilus influenzae, Branhamella catarrhalis, Neisseria gonorrhoeae, Enterobacteriaceae, and Bacteroides species possess beta-lactamases that hydrolyze penicillins and cephalosporins. The most common plasmid-mediated beta-lactamase is the TEM enzyme (Richmond-Sykes type IIIa), which is present in Hemophilus, Neisseria, and Enterobacteriaceae. One technique to overcome bacterial resistance has been the development of beta-lactamase inhibitors. Clavulanic acid is a beta-lactamase inhibitor that inhibits the beta-lactamases of S. aureus, Hemophilus, Neisseria, Branhamella, Eschericia coli, Klebsiella, and Bacteroides. Clavulanate acts as a "suicide" inhibitor, forming a stable enzyme complex that binds to serine at the active site of the enzyme. Clavulanate readily crosses the outer cell wall of most Enterobacteriaceae to interact with beta-lactamases in the periplasmic space. Clavulanate does not inhibit beta-lactamases such as the Richmond-Sykes type I enzymes found in Pseudomonas aeruginosa, Enterobacter, and Citrobacter species, which are inducible enzymes that function primarily as cephalosporinases.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3907341     DOI: 10.1016/0002-9343(85)90123-8

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  15 in total

1.  Selling services becoming increasingly important to bottom line, hospitals say.

Authors:  C Johnston
Journal:  CMAJ       Date:  1992-12-15       Impact factor: 8.262

2.  Acts of Endearment: Attending to the affectional bonds between physicians and patients.

Authors:  G G Stephens
Journal:  Can Fam Physician       Date:  1992-12       Impact factor: 3.275

3.  In vitro activities of cefoperazone and sulbactam singly and in combination against cefoperazone-resistant members of the family Enterobacteriaceae and nonfermenters.

Authors:  R J Fass; W W Gregory; R F D'Amato; J M Matsen; D N Wright; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

Review 4.  The diet game. Weighing the options.

Authors:  D Lemaire
Journal:  Can Fam Physician       Date:  1993-03       Impact factor: 3.275

Review 5.  Clinical pharmacokinetics of enzyme inhibitors in antimicrobial chemotherapy.

Authors:  I D Watson; M J Stewart; D J Platt
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

6.  In vitro evaluations of aminopenicillin/beta-lactamase inhibitor combinations.

Authors:  R N Jones
Journal:  Drugs       Date:  1988       Impact factor: 9.546

7.  Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important beta-lactamases.

Authors:  D J Payne; R Cramp; D J Winstanley; D J Knowles
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

Review 8.  Pain relief for headaches. Is self-medication a problem?

Authors:  R G Robinson
Journal:  Can Fam Physician       Date:  1993-04       Impact factor: 3.275

Review 9.  Coronary artery bypass surgery. Which patients benefit?

Authors:  C Pollick
Journal:  Can Fam Physician       Date:  1993-02       Impact factor: 3.275

Review 10.  Drug utilisation review (DUR) of the third generation cephalosporins. Focus on ceftriaxone, ceftazidime and cefotaxime.

Authors:  A Adu; C L Armour
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.